Article Summary
周宇杰,金红艳,柳艳飞,葛四平,刘正刚.子宫内膜癌组织KIF20A、LAPTM4B-35表达与临床病理特征及预后的关系研究[J].现代生物医学进展英文版,2022,(5):925-929.
子宫内膜癌组织KIF20A、LAPTM4B-35表达与临床病理特征及预后的关系研究
Relationship Study between the Expression of KIF20A and LAPTM4B-35 and Clinicopathological Features and Prognosis in Endometrial Carcinoma
Received:August 23, 2021  Revised:September 18, 2021
DOI:10.13241/j.cnki.pmb.2022.05.026
中文关键词: 子宫内膜癌  KIF20A  LAPTM4B-35  预后  临床病理特征
英文关键词: Endometrial carcinoma  KIF20A  LAPTM4B-35  Prognosis  Clinicopathological features
基金项目:湖北省卫生健康委员会联合基金项目(WJ2019H226)
Author NameAffiliationE-mail
周宇杰 武汉科技大学附属普仁医院肿瘤科 湖北 武汉 430081 jiandan126foxmail@126.com 
金红艳 武汉科技大学附属普仁医院肿瘤科 湖北 武汉 430081  
柳艳飞 武汉科技大学附属普仁医院肿瘤科 湖北 武汉 430081  
葛四平 武汉科技大学附属普仁医院肿瘤科 湖北 武汉 430081  
刘正刚 武汉科技大学附属普仁医院肿瘤科 湖北 武汉 430081  
Hits: 678
Download times: 408
中文摘要:
      摘要 目的:探讨子宫内膜癌组织驱动蛋白家族成员20A(KIF20A)、溶酶体相关4次跨膜蛋白B-35(LAPTM4B-35)表达与临床病理特征及预后的关系。方法:选择2012年4月至2015年8月期间于我院行手术治疗的80例子宫内膜癌患者作为研究对象。检测子宫内膜癌组织以及距离肿瘤边缘2 cm以上癌旁组织中KIF20A、LAPTM4B-35 mRNA表达水平。分析子宫内膜癌组织中KIF20A、LAPTM4B-35 mRNA表达与临床病理特征的关系。分析不同KIF20A、LAPTM4B-35 mRNA表达患者5年总生存率的差异。分析子宫内膜癌患者预后的影响因素。结果:与癌旁组织相比,子宫内膜癌组织中KIF20A、LAPTM4B-35 mRNA表达水平明显升高,差异有统计学意义(P<0.05)。有淋巴结转移以及FIGO分期Ⅲ期患者的癌组织KIF20A、LAPTM4B-35 mRNA表达水平明显高于无淋巴结转移以及FIGO分期I~II期患者的癌组织,差异有统计学意义(P<0.05)。KIF20A低表达组患者5年总生存率明显高于KIF20A高表达组;LAPTM4B-35低表达组患者5年总生存率明显高于LAPTM4B-35高表达组患者,差异有统计学意义(P<0.05)。Cox回归分析结果显示:FIGO分期Ⅲ期、有淋巴结转移、KIF20A mRNA高表达和LAPTM4B-35 mRNA高表达是子宫内膜癌患者预后的影响因素(P<0.05)。结论:在子宫内膜癌组织中KIF20A、LAPTM4B-35 mRNA表达水平升高,有淋巴结转移、FIGO分期较高患者癌组织KIF20A、LAPTM4B-35 mRNA表达水平上调。KIF20A 、LAPTM4B-35高表达患者5年总生存率下降。
英文摘要:
      ABSTRACT Objective: To investigate the relationship between the expression of kinesin family member 20A (KIF20A) and lysosome-associated protein transmembrane 4 beta-35 (LAPTM4B-35) and clinicopathological features and prognosis in endometrial carcinoma. Methods: 80 patients with endometrial carcinoma who underwent surgery in our hospital from April 2012 to August 2015 were selected as the research objects. The expression levels of KIF20A and LAPTM4B-35 mRNA in endometrial carcinoma tissues and paracancerous tissue more than 2cm away from the tumor edge were detected. The relationship between the expression of KIF20A, LAPTM4B-35 mRNA and clinicopathological features in endometrial carcinoma were analyzed. The difference of 5-year overall survival rate in patients with different KIF20A and LAPTM4B-35 mRNA expression was analyzed. The prognostic factors of patients with endometrial carcinoma were analyzed. Results: Compared with the paracancerous tissue, the expression levels of KIF20A and LAPTM4B-35 mRNA in endometrial carcinoma tissues were significantly increased, and the differences were statistically significant (P<0.05). The expression levels of KIF20A and LAPTM4B-35 mRNA in carcinoma tissues of patients with lymph node metastasis and FIGO stage III were significantly higher than those of patients without lymph node metastasis and FIGO stage I ~ II, with statistical significance(P<0.05). The 5-year overall survival rate of patients with low KIF20A expression group was significantly higher than that of patients with high KIF20A expression group. The 5-year overall survival rate of patients with low LAPTM4B-35 expression group was significantly higher than that of patients with high LAPTM4B-35 expression group, with statistical significance(P<0.05). Cox regression analysis showed that FIGO stage III, lymph node metastasis, high expression of KIF20A mRNA and LAPTM4B-35 mRNA were the prognostic factors of patients with endometrial carcinoma(P<0.05). Conclusion: The expression levels of KIF20A and LAPTM4B-35 mRNA in endometrial carcinoma tissues are increased, and the expression levels of KIF20A and LAPTM4B-35 mRNA in carcinoma tissues of patients with lymph node metastasis and higher FIGO stage are increased. The 5-year overall survival rate of patients with high expression of KIF20A and LAPTM4B-35 decreased.
View Full Text   View/Add Comment  Download reader
Close